News
Actio Biosciences has closed a Series B financing round, raising $66m for advancing the genetics-driven small molecule ...
BioOrbit CEO Dr Katie King said that pre-clinical studies of the crystals produced in space could start as early as 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback